Page 5 - Treating Fields News Today

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future

Novocure chose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life Novocure (NASDAQ: NVCR) today announced it has opened a

Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients Pre-clinical research shows the potential for

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program - read this article along with other careers information, tips and advice on BioSpace

Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck Co., Inc., Rahway, NJ, USA.

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric... | June 3, 2022

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields

Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET...

Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in